Subscribe to RSS
DOI: 10.1055/s-0040-1712147
Ethical Issues in Pediatric Regulatory Studies Involving Placebo Treatment
Abstract
Separate pediatric studies for antiepileptic drugs (AEDs) emerged with general separate drug approval in children and were defined by the U.S. Food and Drug Administration (FDA) as <17 years and by the European Union (EU) as <18 years. These administrative age limits are necessary in pediatrics, but they correspond variably with the physiological maturity of young patients and are not helpful for therapeutic decisions or as study inclusion criteria. AEDs are often effective for partial onset seizures (POS) in 2 to 17-year-olds as well as in ≥18-year-olds, if dosed correctly. Separate pediatric AED studies assume no difference between the legal and the physiological meaning of the word “child.” While the FDA now accepts efficacy of AEDs in POS in children ≥2 years, the EU still requires separate “pediatric” studies. For retigabine it waived all pediatric studies after having required 20 such studies over several years. We feel the current regulation creates a situation where many studies in children are done unnecessarily; we question the ethics of such an approach, which in our view, is morally wrong. Critical publications contributed to the FDA's shift of opinion for AEDs in POS but did not address the blur of different meanings of the word “child.”
Keywords
pediatric drug development - pediatric clinical pharmacology - antiepileptic drugs - pharmacokinetics - pharmacodynamicsPublication History
Received: 27 February 2020
Accepted: 31 March 2020
Article published online:
04 June 2020
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Stuttgart · New York
-
References
- 1 Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342 (05) 314-319
- 2 Chen Z, Brodie MJ, Kwan P. What has been the impact of new drug treatments on epilepsy?. Curr Opin Neurol 2020; 33 (02) 185-190
- 3 Rägo L, Santo B. Drug regulation: history, present and future. In: van Boxtel CJ, Santo B, Edwards IR. , eds. Drug Benefits and Risks: International Textbook of Clinical Pharmacology. Revised 2nd ed. Uppsala: IOS Press & Uppsala Monitoring Centre; 2008: 65-77
- 4 Penry JK. Principles for clinical testing of antiepileptic drugs. Epilepsia 1973; 14 (04) 451-458
- 5 Commission on Antiepileptic Drugs of the International League Against Epilepsy. Workshop on antiepileptic drug trials in children. Epilepsia 1991; 32 (02) 284-285
- 6 Sheridan PH, Jacobs MP. The development of antiepileptic drugs for children. Report from the NIH workshop, Bethesda, Maryland, February 17-18, 1994. Epilepsy Res 1996; 23 (01) 87-92
- 7 Sun H, Temeck JW, Chambers W, Perkins G, Bonnel R, Murphy D. Extrapolation of efficacy in pediatric drug development and evidence-based medicine: progress and lessons learned. Ther Innov Regul Sci 2017; 2017: 1-7
- 8 FDA 2019. Drugs for treatment of partial onset seizures: full extrapolation of efficacy from adults to pediatric patients 2 years of age and older guidance for industry. Available at: https://www.fda.gov/media/130449/download
- 9 Pellock JM, Carman WJ, Thyagarajan V, Daniels T, Morris DL, D'Cruz O. Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review. Neurology 2012; 79 (14) 1482-1489
- 10 Pellock JM, Arzimanoglou A, D'Cruz O, Holmes GL, Nordli D, Shinnar S. Pediatric Epilepsy Academic Consortium for Extrapolation. Extrapolating evidence of antiepileptic drug efficacy in adults to children ≥2 years of age with focal seizures: the case for disease similarity. Epilepsia 2017; 58 (10) 1686-1696
- 11 Arzimanoglou A, D'Cruz O, Nordli D, Shinnar S, Holmes GL. Pediatric Epilepsy Academic Consortium for Extrapolation (PEACE). A review of the new antiepileptic drugs for focal-onset seizures in pediatrics: role of extrapolation. Paediatr Drugs 2018; 20 (03) 249-264
- 12 Wadsworth I, Jaki T, Sills GJ. , et al. Clinical drug development in epilepsy revisited: a proposal for a new paradigm streamlined using extrapolation. CNS Drugs 2016; 30 (11) 1011-1017
- 13 Shirkey H. Therapeutic orphans. J Pediatr 1968; 72 (01) 119-120
- 14 Hirschfeld S, Saint-Raymond A. Pediatric regulatory initiatives. Handb Exp Pharmacol 2011; 205: 245-268
- 15 Hirschfeld S. History of pediatric labeling. Available at: https://www.slideserve.com/marlin/history-of-pediatric-labeling . Accessed April, 2020
- 16 Regulation (EC) No. 1901/2006 of the European Parliament and of the Council of 12 December 2006 on Medicinal Products for Paediatric Use and Amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32006R1901&from=EN . Accessed April, 2020
- 17 Rose K, Grant-Kels JM. The meanings of “pediatric drug development”. Ther Innov Regul Sci 2019; 53 (06) 767-774
- 18 Dunne J, Rodriguez WJ, Murphy MD. , et al. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics 2011; 128 (05) e1242-e1249
- 19 Cone Jr TE. Secular acceleration of height and biologic maturation in children during the past century. J Pediatr 1961; 59: 736-740
- 20 Komlos J, Lauderdale BE. The mysterious trend in American heights in the 20th century. Ann Hum Biol 2007; 34 (02) 206-215
- 21 World Medical Association. (WMA) Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013. Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/.
- 22 Donohue J. A history of drug advertising: the evolving roles of consumers and consumer protection. Milbank Q 2006; 84 (04) 659-699
- 23 Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations, committee on drugs. American Academy of Pediatrics. Pediatrics 1995; 95 (02) 286-294
- 24 Rose K. The challenges of pediatric drug development. Curr Ther Res Clin Exp 2019; 90: 128-134
- 25 Rose K, Neubauer D, Grant-Kels JM. Rational use of medicine in children—the conflict of interests story. A Review. Rambam Maimonides Med J 2019; 10 (03) e0018 . Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649781/pdf/rmmj-10-3-e0018.pdf. Accessed April, 2020
- 26 UN Declaration of the Rights of the Child. 1959 . Available at: https://www.humanium.org/en/declaration-rights-child-2/
- 27 Li JS, Eisenstein EL, Grabowski HG. , et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 2007; 297 (05) 480-488
- 28 Ward RM, Benjamin Jr DK, Davis JM. , et al. The need for pediatric drug development. J Pediatr 2018; 192: 13-21
- 29 Written Requests Issued. Available at: https://www.fda.gov/drugs/development-resources/written-requests-issued
- 30 FDA 2001. The Pediatric Exclusivity Provision. January 2001. Status Report to Congress. Available at: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049915.pdf
- 31 EMA. 2018. Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-3_en.pdf
- 32 FDA 2019. Drugs for treatment of partial onset seizures: full extrapolation of efficacy from adults to pediatric patients 2 years of age and older guidance for industry. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drugs-treatment-partial-onset-seizures-full-extrapolation-efficacy-adults-pediatric-patients-2-years
- 33 CLINICAL REVIEW. Available at: https://www.fda.gov/media/84835/download
- 34 Cross-Discipline Team Leader Review. . Available at: https://www.fda.gov/media/109082/download
- 35 Retigabine PIP. EMEA-000116–PIP01–07–M08. Available at: https://www.ema.europa.eu/en/documents/pip-decision/p/0009/2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf.
- 36 Retigabine PIP. EMEA-000116–PIP01–07–M09. Available at: https://www.ema.europa.eu/en/documents/pip-decision/p/0299/2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf . Accessed April, 2020
- 37 Hardin AP, Hackell JM. Committee on Practice and Ambulatory Medicine. Age limit of pediatrics. Pediatrics 2017; 140 (03) e20172151
- 38 EMA. 2004. Evidence of harm from off-label or unlicensed medicines in children. Available at: https://www.ema.europa.eu/en/documents/other/evidence-harm-label-unlicensed-medicines-children_en.pdf
- 39 Adamson PC. Improving the outcome for children with cancer: development of targeted new agents. CA Cancer J Clin 2015; 65 (03) 212-220
- 40 Rose K, Neubauer D, Grant-Kels JM. Too many avoidable suicides occur worldwide in young patients. Rambam Maimonides Med J 2019 10(04):
- 41 Philip AG. The evolution of neonatology. Pediatr Res 2005; 58 (04) 799-815
- 42 EMA 10-year Report to the European Commission. General report on the experience acquired as a result of the application of the Paediatric Regulation. Available at: https://ec.europa.eu/health/sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf
- 43 Phase 2 study of ipilimumab in children and adolescents (12 to <18 years) with previously treated or untreated, unresectable stage III or stage IV malignant melanoma. Available at: https://clinicaltrials.gov/ct2/show/NCT01696045
- 44 BRIM-P. A study of vemurafenib in pediatric patients with stage IIIC or stage IV melanoma harboring BRAFV600 mutations. Available at: https://www.clinicaltrials.gov/ct2/show/NCT01519323
- 45 Geoerger B, Bergeron C, Gore L. , et al. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer 2017; 86: 358-363
- 46 Rose K, Grant-Kels JM. Pediatric melanoma—the whole (conflicts of interest) story. Int J Womens Dermatol 2018; 5 (02) 110-115
- 47 International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct. Reporting, editing, and publication of scholarly work in medical journals. Available at: http://www.icmje.org/recommendations/
- 48 Waubant E, Banwell B, Wassmer E. , et al; IPMSSG. Clinical trials of disease-modifying agents in pediatric MS: opportunities, challenges, and recommendations from the IPMSSG. Neurology 2019; 92 (22) e2538-e2549
- 49 Rose K, Fumi L, Grant-Kels JM. Reader response: clinical trials of disease-modifying agents in pediatric MS: opportunities, challenges, and recommendations from the IPMSSG. Neurology 31 May 2019. Available at: https://n.neurology.org/content/reader-response-clinical-trials-disease-modifying-agents-pediatric-ms-opportunities
- 50 Beecher HK. Ethics and clinical research. N Engl J Med 1966; 274 (24) 1354-1360
- 51 Rose CD. Ethical conduct of research in children: pediatricians and their IRB (Part 1 of 2). Pediatrics 2017; 139 (05) e20163648